Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA.

Fiebelkorn AP, Lawler J, Curns AT, Brandeburg C, Wallace GS.

Emerg Infect Dis. 2013;19(9):1411-7. doi: 10.3201/eid1909.130299.

2.

Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).

McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS; Centers for Disease Control and Prevention.

MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34. Erratum in: MMWR Recomm Rep. 2015 Mar 13;64(9):259.

3.

Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010.

Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, Lizama A, Diras D, Mathew A, Camacho EJ, Monforte MN, Chen TH, Mahamud A, Kutty PK, Hickman C, Bellini WJ, Seward JF, Gallagher K, Fiebelkorn AP.

Pediatr Infect Dis J. 2013 Apr;32(4):374-80. doi: 10.1097/INF.0b013e318279f593.

PMID:
23099425
4.

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12.

5.

Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak.

Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, Lawler J, McLean HQ, Pollock L, Rausch-Phung E, Schulte C, Valure B, Armstrong GL, Gallagher K.

Pediatrics. 2012 Dec;130(6):e1567-74. doi: 10.1542/peds.2012-0177. Epub 2012 Nov 5.

6.

Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City.

Livingston KA, Rosen JB, Zucker JR, Zimmerman CM.

Vaccine. 2014 Jan 9;32(3):369-74. doi: 10.1016/j.vaccine.2013.11.021. Epub 2013 Nov 16.

PMID:
24252695
7.

Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.

Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.

Pediatr Infect Dis J. 2008 Aug;27(8):724-30. doi: 10.1097/INF.0b013e318170bb22. Erratum in: Pediatr Infect Dis J. 2013 Apr;32(4):e163.

PMID:
18600190
8.

Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.

Eur J Pediatr. 2012 Mar;171(3):463-70. doi: 10.1007/s00431-011-1569-4. Epub 2011 Sep 21.

PMID:
21935584
9.

Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.

Wang Z, Yan R, He H, Li Q, Chen G, Yang S, Chen E.

PLoS One. 2014 Feb 20;9(2):e89361. doi: 10.1371/journal.pone.0089361. eCollection 2014.

10.

Vaccines for measles, mumps and rubella in children.

Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD004407. doi: 10.1002/14651858.CD004407.pub3. Review.

PMID:
22336803
11.

Ongoing outbreak of mumps infection in Oban, Scotland, November 2010 to January 2011.

Walker J, Huc S, Sinka K, Tissington A, Oates K.

Euro Surveill. 2011 Feb 24;16(8). pii: 19803.

12.

Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.

Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.

Pediatr Infect Dis J. 2005 Dec;24(12):1083-8.

PMID:
16371870
13.
14.

An outbreak of mumps in the metropolitan area of Walsall, UK.

Pugh RN, Akinosi B, Pooransingh S, Kumar J, Grant S, Livesley E, Linnane J, Ramaiah S.

Int J Infect Dis. 2002 Dec;6(4):283-7.

PMID:
12718822
15.

Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.

Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B, Shamshiri AR, Khairkhah M, Shekari Ebrahimabad H, Karimi A.

Arch Iran Med. 2013 Jan;16(1):38-41. doi: 013161/AIM.0012.

16.

Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.

Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H.

J Trop Pediatr. 2011 Oct;57(5):347-51. doi: 10.1093/tropej/fmq102. Epub 2010 Nov 14.

PMID:
21078605
17.

Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?

Llenas-García J, Rubio R, Hernando A, Arrazola P, Pulido F.

AIDS Care. 2013 Aug;25(8):980-9. doi: 10.1080/09540121.2012.748881. Epub 2012 Dec 17.

PMID:
23244745
18.

Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.

Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M.

Vaccine. 2014 Feb 26;32(10):1147-52. doi: 10.1016/j.vaccine.2014.01.002. Epub 2014 Jan 15.

PMID:
24440207
19.

[Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].

Zäch K, Nicoara C, Germann D, Matter L.

Schweiz Med Wochenschr. 1998 Apr 25;128(17):649-57. German.

PMID:
9622837

Supplemental Content

Support Center